Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095460 | 0.90 | NR1I2 (0.47) | P2RX3CYP2C9DGAT2GABRA5NR1I2 | |
| SCHEMBL13092826 | 0.89 | CYP2C9 (0.48) | P2RX3CYP2C9DGAT2GABRA5NR1I2 | |
| SCHEMBL13095442 | 0.87 | P2RX3 (0.44) | P2RX3CYP2C9DGAT2GABRA5NR1I2 | |
| SCHEMBL13095453 | 0.84 | P2RX3 (0.44) | P2RX3CYP2C9GABRA5NR1I2P2RX2 | |
| SCHEMBL21091765 | 0.83 | P2RX3 (0.38) | P2RX3CYP2C9GABRA5CNR2CNR1 | |
| SCHEMBL13092766 | 0.79 | NR1I2 (0.48) | P2RX3CYP2C9DGAT2GABRA5NR1I2 | |
| SCHEMBL13095459 | 0.79 | DGAT2 (0.43) | DGAT2GABRA5CNR2BDKRB1 | |
| SCHEMBL13095503 | 0.78 | NR1I2 (0.50) | P2RX3CYP2C9NR1I2P2RX2 | |
| SCHEMBL21092174 | 0.78 | KCNJ1 (0.45) | P2RX3CYP2C9GABRA5P2RX2THRB | |
| SCHEMBL13095435 | 0.77 | P2RX3 (0.48) | P2RX3CYP2C9DGAT2GABRA5NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | P2RX3 1/4885CYP2C9 4126/4885DGAT2 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.